Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT01920932
PHASE2

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Sponsor: St. Jude Children's Research Hospital

View on ClinicalTrials.gov

Summary

This pilot phase II trial studies how well giving brentuximab vedotin, combination chemotherapy, and radiation therapy works in treating younger patients with stage IIB, IIIB or IV Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer killing substances to them. Drugs used in chemotherapy, such as etoposide, prednisone, doxorubicin hydrochloride, cyclophosphamide, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving brentuximab vedotin with combination chemotherapy may kill more cancer cells and reduce the need for radiation therapy.

Official title: Adcetris (Brentuximab Vedotin), Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL)

Key Details

Gender

All

Age Range

Any - 18 Years

Study Type

INTERVENTIONAL

Enrollment

77

Start Date

2013-08-12

Completion Date

2028-05

Last Updated

2025-12-03

Healthy Volunteers

No

Interventions

DRUG

brentuximab vedotin

Given intravenously (IV).

DRUG

etoposide

Given IV.

DRUG

prednisone

Given orally (PO).

DRUG

doxorubicin

Given IV.

DRUG

cyclophosphamide

Given IV.

DRUG

Dacarbazine(R)

Given IV.

DRUG

filgrastim

Given subcutaneously (SQ) as clinically indicated.

OTHER

quality of life assessment

Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.

RADIATION

radiation therapy

At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.

Locations (6)

Lucile Packard Children's Hospital Stanford University

Palo Alto, California, United States

St. Jude Midwest Affiliate

Peoria, Illinois, United States

Maine Children's Cancer Program (MCCP)

Scarborough, Maine, United States

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

Dana-Farber Harvard Cancer Center

Boston, Massachusetts, United States

St. Jude Children's Research Hospital

Memphis, Tennessee, United States